3 Monster Stocks in the Making to Buy Right Now
They're small now, but these stocks could grow much larger.
Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio
Could Zealand Pharma be a better option for growth-oriented investors?
Invest in the GLP-1 Drug Market With This New ETF
The market for anti-obesity drugs is massive one, worth potentially $100 billion or more based on some ...
Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.
The risk is higher, but so is the upside when it comes to Zealand Pharma.